Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Carmen J, Calfa"'
Autor:
Kelsey A, Klute, Michael, Rothe, Elizabeth, Garrett-Mayer, Pam K, Mangat, Reza, Nazemzadeh, Kathleen J, Yost, Herbert L, Duvivier, Eugene R, Ahn, Timothy L, Cannon, Olatunji B, Alese, John C, Krauss, Ramya, Thota, Carmen J, Calfa, Crystal S, Denlinger, Raegan, O'Lone, Susan, Halabi, Gina N, Grantham, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 6
TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results of a cohort of patients with colorectal cancer
Autor:
Kelsey A. Klute, Michael Rothe, Elizabeth Garrett-Mayer, Pam K. Mangat, Reza Nazemzadeh, Kathleen J. Yost, Herbert L. Duvivier, Eugene R. Ahn, Timothy L. Cannon, Olatunji B. Alese, John C. Krauss, Ramya Thota, Carmen J. Calfa, Crystal S. Denlinger, Raegan O'Lone, Susan Halabi, Gina N. Grantham, Richard L. Schilsky
Publikováno v:
JCO Precision Oncology.
PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results of a cohort of patients with colorecta
Autor:
Kristopher Wentzel, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Li Ding, Evan Pisick, Mridula Krishnan, Deepti Behl, Olatunji B. Alese, Carmen J. Calfa, Kathrine A. Cooper, Herbert L. Duvivier, Raghava Reddy Induru, Janet C. Ruzich, Song Zhao, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Publikováno v:
Cancer Research. 83:CT231-CT231
Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with PTEN mut treated wi
Autor:
Kathryn F. Mileham, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Herbert L. Duvivier, Carmen J. Calfa, Carrie L. Dul, Alissa S. Marr, Eugene R. Ahn, Deepti Behl, Michael J. Hall, Inderjit Mehmi, Anu Gaba, Rom Leidner, Mark M. Zalupski, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Publikováno v:
Cancer Research. 83:CT226-CT226
Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors and MET amp or mut treat
Autor:
Eugene R, Ahn, Pam K, Mangat, Elizabeth, Garrett-Mayer, Susan, Halabi, Elie G, Dib, Daniel E, Haggstrom, Kathryn B, Alguire, Carmen J, Calfa, Timothy L, Cannon, Pamela A, Crilley, Anu G, Gaba, Alissa S, Marr, Ashish, Sangal, Ramya, Thota, Kaitlyn R, Antonelli, Samiha, Islam, Andrew L, Rygiel, Suanna S, Bruinooge, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 4
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be dru
Autor:
Julie G, Fisher, David, Tait, Elizabeth, Garrett-Mayer, Susan, Halabi, Pam K, Mangat, Julian C, Schink, Ricardo H, Alvarez, Dan, Veljovich, Timothy L, Cannon, Pamela A, Crilley, Theodore, Pollock, Carmen J, Calfa, Tareq, Al Baghdadi, Ramya, Thota, Nicole, Fleming, Jared A, Cotta, Andrew L, Rygiel, Sasha L, Warren, Richard L, Schilsky
Publikováno v:
Targeted oncology. 15(6)
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug target
Autor:
Charles L. Wiseman, Saveri Bhattacharya, William V. Williams, Carmen J. Calfa, Daniel L. Adams, Vivekananda (Vivek) Sunkari, Jacqueline Galeas, George E. Peoples, Diane DaSilva, Jarrod P. Holmes, Shaker R. Dakhil, Ajay Kundra, Markus D. Lacher
Publikováno v:
Cancer Research. 80:5588-5588
SV-BR-1-GM is a GM-CSF secreting breast cancer cell line that also expresses HLA class I & II antigens. Irradiated SV-BR-1-GM is used in a regimen including pre-dose low-dose cyclophosphamide and post-dose local interferon-α2b. The SV-BR-1-GM regime
Autor:
Carmen J Calfa, Angela Yehl, Julie G Wilkinson, Andrea D Ivory, Mindy M Williams, Stephanie E Hoogenbergen, James M. Pann
Publikováno v:
Cancer Research. 75:P1-17
Introduction. Disparities in the detection of breast cancer persist despite efforts to reach underserved populations and increase mammography utilization. Black and Hispanic women are more likely to be diagnosed at a later stage compared to White wom